Welcome to our dedicated page for Imunon news (Ticker: $IMNN), a resource for investors and traders seeking the latest updates and insights on Imunon stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Imunon's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Imunon's position in the market.
IMUNON (NASDAQ: IMNN) announced that an abstract detailing a Phase 2 study involving IMNN-001 combined with bevacizumab (Avastin) and neoadjuvant chemotherapy for advanced epithelial ovarian cancer patients has been accepted for presentation at the American Society of Clinical Oncology (ASCO) annual meeting. The presentation will occur on June 3, 2024, during the Gynecologic Cancer session at the event in Chicago, which runs from May 31 to June 4.
Lead investigator Dr. Amir A Jazaeri from The University of Texas MD Anderson Cancer Center will present the study, which aims to evaluate the effect of this combination therapy in newly diagnosed patients. The study is actively recruiting participants in the U.S. and is substantially funded by Break Through Cancer.
According to Dr. Sebastien Hazard, IMUNON’s Chief Medical Officer, the synergy observed between IMNN-001 and bevacizumab in pre-clinical experiments is promising, and the company aims to complete enrollment quickly to address this critical clinical question.
IMUNON, Inc. (NASDAQ: IMNN) announces the activation of the first site for its Phase 1 study with IMNN-101, a seasonal Covid-19 vaccine, utilizing its proprietary PlaCCine platform. The study aims to evaluate safety, tolerability, and immune response in healthy adults. Topline results are expected by year-end. IMNN-101 is designed to protect against the SARS-CoV-2 Omicron XBB1.5 variant, with potential advantages over mRNA vaccines in terms of immune protection and vaccine stability.
IMUNON, Inc. (NASDAQ: IMNN) reported financial results for Q1 2024, highlighting clinical development programs with promising results for IMNN-001 immunotherapy and PlaCCine modality. The company also appointed Dr. Stacy Lindborg as President and CEO. Recent developments include positive data in advanced ovarian cancer studies and progress in developing a seasonal COVID-19 booster vaccine. IMUNON received non-dilutive funding and reported a net loss of $4.9 million for Q1 2024.
IMUNON, Inc. (NASDAQ: IMNN) appointed Dr. Stacy R. Lindborg as President and CEO, bringing extensive experience in drug development. Dr. Lindborg takes over at a critical time with key clinical milestones approaching. IMNN-001 results in advanced ovarian cancer expected mid-summer, while Phase 1 data for IMNN-101 in seasonal COVID-19 are anticipated by year-end.
IMUNON, Inc. (NASDAQ: IMNN) will host a conference call on May 13, 2024, to discuss financial results for the first quarter of 2024. The company will provide updates on its clinical development programs, including IMNN-001 for ovarian cancer treatment and the PlaCCine modality for next-generation vaccines.
